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Abstract
The outcome of patients underwent to
allogeneic stem cell transplantation (allo-
SCT) is closely related to graft versus host
disease (GvHD) and graft versus leukemia
(GvL) effects which can be mediated by
mHAgs. 23 mHAgs have been identified and
reported to be differently correlated with
GVHD or GVL and the aim of this work was
develop a method to genotype the mHAgs
described so far. For this study we used
MALDI-TOF iPLEX Gold Mass Array
technology. We tested 46 donor/recipient
matched pairs that underwent allo-SCT
because of Philadelphia positive (Ph+)
chronic myeloid leukemia (n=29) or Ph+
acute lymphoblastic leukemia (n=17). Our
data show that sibling pairs had a lesser
number of mHAgs mismatches compared to
MUD pairs. Notably, donor/recipient
genomic mismatch on DPH1 was correlated
with an increased risk of acute GvHD and
LB-ADIR-1R mismatch on graft versus host
direction was correlated with a better RFS
with no increase of GvHD risk. Our work
provides a simple, accurate and highly
automatable method for mHAgs genotyping
and suggest the role of mHAgs in addressing
the immune reaction between donor and
host.
Introduction
Allogeneic stem cell transplantation
(allo-SCT) may be the only cure for patients
affected by acute myeloid or lymphoid
leukemia, or other hematological diseases
such as lymphomas or multiple myeloma.1
The curative effects of allo-SCT are
closely related to graft versus leukemia
(GvL). However the severity of the graft
versus host disease (GvHD) may override
the GvL benefit and worsen the outcome of
allotransplanted patients.1-3 Despite a full
major HLA antigens (MHAgs)
compatibility, minor histocompatibility
antigens (mHAgs) can also play a pivotal
role in conditioning both GvL and GvHD
response in HLA full-matched allo-SCT.
Evidence from experimental and clinical
studies on HLA-identical allo-SCT suggest
that GvL and GvHD may be driven by donor
T cell responses against disparate mHAgs.4-
9 Indeed, mHAgs are polymorphic
HLA-bound peptides derived from cellular
proteins that can induce powerful
alloreactive T cell responses. The mHAgs
recipient-donor disparity may arise from a
genomic variation in the coding region of the
gene that leads to differences in the amino
acid sequence of the homologous protein
and, in most cases, it may depend on a non-
synonymous single nucleotide
polymorphism (nsSNP) or on a
deletion.7,10,11 Recent advances in the
molecular identification of mHAgs have
significantly expanded our knowledge to a
total of 23 autosome-coded mHAgs and 10
Y-chromosome coded mHAgs, leading to an
increased interest in the clinical application
of mHAgs typing. Although several mHAgs,
including Y-chromosome encoded mHAgs,
are ubiquitously expressed, an increasing
number of autosomal-encoded mHAgs is
being identified as expressed exclusively by
hematopoietic cells or by their malignant
counterparts.12-21
About this, ACC-1, ACC-2 and HA-2
have been correlated with the beneficial GvL
effects, while some mHAgs disparities,
CD31, HA-5, HA-8 and UGT2B17, have
been found to be involved in the induction
of GvHD.8,22-28
The molecular identification of GvHD-
and GvL-associated mHAgs could allow the
evaluation of the clinical impact of mHAgs
mismatches and their specific T cell
responses triggered by allo-SCT. Several
studies in HLA-matched allo-SCT reported
an association between mHAgs mismatches
and the clinical outcome,29-33 but other
studies have not confirmed these
observations.7,24
The heterogeneity of techniques suitable
for mHAgs typing (SSP-PCR and Luminex)
as well as the complexity of integrating
mHAgs typing data and clinical information
are likely the main reasons that do not
facilitate the routinary evaluation of mHAgs
in clinics.34-36 In our study, we set up a
new method for mHAgs genotyping based
on Matrix Assisted Laser Desorption
Ionization Time-of-Flight (MALDI-TOF)
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mass spectrometry (MS) and we tested it in
a training set of donor-recipient pairs with
the aim to propose a simple and
standardizable methodology able to
overcome the limits of the conventional
methods and to make mHAgs genotyping
suitable for clinical application.37-38
Materials and Methods
Patients and transplant procedures
For this study, we tested the MALDI-
TOF iPLEX Gold method on a cohort of Ph+
CML and Ph+ ALL patients who underwent
allo-SCT at six Italian Centres from 1990 to
2011. To this purpose, we retrospectively
selected 46 donor-recipient pairs fully HLA
compatible for HLA-A, -B, -C, -DRB1 and
-DQB1 alleles, according to SSP-PCR high
resolution molecular methods. Out of the 46
selected cases, 29 were Ph+ CML and 17
were Ph+ ALL patients who underwent allo-
SCT by sibling (29 cases, 63%) or MUD (17
cases, 37%).
GvHD effects, either acute or chronic,
were defined according to the Glucksberg
scale and NHI criteria, respectively, and they
were reported as cumulative incidence.
Relapse free survival (RFS) was calculated
using Kaplan-Meier method and it was
assumed as an indicator of GVL effect.39-40
All patients provided informed consent
according to the policy of each participating
Centre. Patients and transplant features are
reported in Table 1.
mHAgs’s biological characteristics
and definitions
The HLA matched donor-recipient pairs
evaluated for this study were genotyped for
a panel of 23 mHAgs (and causal SNPs).
The biological characteristics of each mHAg
(gene, locus, SNP reference number,
nucleotide switch and HLA restriction) are
detailed in Table 2. We specify that CD31
exists in two isoforms (CD31125 and
CD31563) because it results from two
different SNPs (rs668 and rs12953,
respectively). We genotyped both SNPs, but
we considered the two isoforms together
during the analysis because of the strong
linkage between the two SNPs. On the
contrary, the SNP rs2289702 determine two
different mHAgs, ACC-4 and ACC-5,
according to the HLA molecule that present
them.
For the purpose of this study,
immunogenic mHAg difference was defined
when within a given donor/recipient pair,
only one individual had an immunogenic
phenotype of a particular mHAg
accompanied by the appropriate HLA
restriction molecule. Genomic mHAg
difference was identified when mHAg
genotypes in donor and recipient were
different, but phenotypically they were either
the same or the mHAg immunogenic
phenotype was not accompanied by the
appropriate HLA restriction molecule. Both
genomic and immunogenic mHAgs
disparities were included in the analysis.
This is due to an incomplete knowledge of
mHAgs because the epitope-prediction
strategy often makes it hard to confirm the
immunogenicity of the predicted putative
mHAgs and there is currently no controlled
way of isolating mHAgs-specific T cells
directed against mHAgs.
mHAgs genotyping by MALDI-TOF
iPLEX Gold technology
For the purpose of our study, the
genomic DNA (gDNA) was extracted using
QIAamp DNA mini Kit (Qiagen) from
peripheral blood mononuclear cells (PBMC)
previously cryopreserved. The PBMC
collection was performed before allo-SCT
for patients and before stem cells harvest for
donors. The purity of gDNA for each sample
was determined by measuring the
absorbance at 260 and 280 nm, with the
A260/A280 values being in the range of 1.5-
1.9, and the concentration of the gDNA was
adjusted to 12 ng/µL. A total of 30 ng of
gDNA was used for genotyping all SNPs.
MS MALDI-TOF iPlex Gold is able to
                             Article
Table 1. Patients and HSCT characteristics.
Characteristic                                                        N.                               %
Age, mean (range)                                                                   36.5                                     17-67
Male                                                                                              27                                         59
Male-female sex mismatch                                                      9                                          19
Matched sibling donor                                                              29                                         63
Matched unrelated donor                                                        17                                         37
Ph + CML                                                                                     29                                         63
          CP                                                                                        23                                         79
          AP/BP                                                                                   6                                          21
Ph + ALL                                                                                      17                                         37
          1st CR                                                                                  12                                         71
          2nd CR                                                                                  2                                          12
          Relapse                                                                               3                                          18
Stem cell source                                                                                                                       
          Mobilized peripheral blood                                          24                                         52
          CD34 ×106/kg, median (range)                                   5.07                                     2.2-8
          CD3 ×106/kg, median (range)                                     162                                    4.7-350
          Bone marrow, n (%)                                                       19                                         48
          CD34 ×106/kg, median (range)                                    3.2                                      2.8-4
          CD3 ×106/kg, median (range)                                     23.5                                     20-40
Interval between diagnosis and SCT                                                                                    
          ≤1 year                                                                               24                                         52
          >1 year                                                                              17                                         37
          Not available                                                                      5                                          11
Date of SCT                                                                                                                                
          1990-1999                                                                           19                                         41
          2000-2012                                                                           27                                         59
Conditioning regimens                                                                                                            
          Busulfan based                                                                27                                         59
          TBI based                                                                          17                                         37
          Others                                                                                2                                           4
GvHD prophylaxis                                                                                                                     
          Cyclosporine/MTX                                                           46                                        100
Gratwohl score                                                                                                                          
          1                                                                                            6                                          13
          2                                                                                           12                                         26
          3                                                                                           11                                         24
          4                                                                                            6                                          13
          5                                                                                            4                                           9
          ≥6                                                                                         1                                           2
          ND                                                                                        6                                          13
CP, chronic phase; AP/BP, accelerate phase/blastic phase; CR, complete remission; TBI, total body irradiation; MTX, methotrexate.
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discriminate the two variants of an SNP in a
very efficient way, so it was considered
suitable for the aim of the study. The
MassARRAY Assay Design software was
used to design 3 different multiplex reactions
to investigate the 23 SNPs. Genotyping was
performed using iPLEX Gold technology
and MassARRAY high-throughput DNA
analysis with matrix-assisted laser
desorption/ionization time-of-flight
(MALDITOF) MS [Agena Bioscience
Inc., San Diego, CA], according to the
manufacturer’s protocol.41 Multiplex design
and primer sequences are shown in Table 3.
The multiple-genotyping assay was
validated using intra- and extra-run controls.
Firstly, a DNA sample (NA10859) from the
CEPH (Centre d’Etude du Polymorphisme
Humain CEPH, Paris, France) panel was
genotyped simultaneously in every single
run. Six mHAgs (ACC-1, ACC-2, ACC-6,
HA-8, HB-1 and LB-ADIR-1R) were
reported. Then, the genotype of each
polymorphism was validated in 10 randomly
selected samples by amplification with PCR
and subsequent direct Sanger Sequencing
(ABI Prism 3730, Applied Biosystems,
Foster City, CA) as gold standard.
Statistical analysis 
For continuous factors, the median and
ranges were calculated. The χ2-test was used
to compare differences in percentage, and
Mann-Whitney U test was used to compare
continuous values. The probability of GvHD
(acute and chronic) was estimated as
cumulative incidence. In GvHD analysis,
competing risks were relapse or death before
the onset of GvHD. Probabilities for RFS
were calculated using the Kaplan-Meier
method.42 RFS was calculated from the date
of allo-SCT until the date of relapse or death,
whichever occurred first. Death in remission
was considered as a competing risk in the
relapse analysis. Differences in RFS were
evaluated by log-rank testing in univariate
analysis. Multivariate analyses were
performed using the Fine and Gray
regression model. The Cox proportional
hazard regression model was used for
multivariate analyses of variables affecting
RFS. The following patient- and transplant-
related variables were analyzed: CML or
ALL diagnosis and type of bcr-abl transcript,
immunogenic/genomic mHAgs mismatches
between donor and recipient, patient age at
SCT, type of donor, patient gender and sex
mismatch between donor and recipient, graft
source, time from diagnosis to HSCT,
conditioning regimen, GvHD prophylaxis
and development of GvHD. All P-values
were 2-sided and P<0.05 was considered
statistically significant. Each SNP was tested
for departures from the Hardy-Weinberg
equilibrium (HWE).
Results
SNPs genotyping by MALDI-TOF
iPLEX Gold technology
The MALDI-TOF iPLEX Gold
technology method was used on a training
                                                                                                                             Article
Table 2. mHAgs biological features.
mHAg                 Gene                Gene                Tissue                   SNP            Nucleotide  HLA                            Ref.
                                                    locus            expressione          reference           switch           Restriction    Caucasian 
                                                                                                                                                                                 frequence               
ACC-1                        Bcl2A1                    15q24.3                Hemopoietic               rs1138357                  G→A                        A*24                      25             [3, 28, 32, 26, 16]
ACC-2                          Bcl2                      15q24.3                Hemopoietic               rs3826007                  G→A                        B*44                      17                [3, 28, 32, 26]
ACC-4                   Catepsina H             15q24-25               Hemopoietic               rs2289702                  G→A                      A*33:03                     0                        [6, 28]
ACC-5                   Catepsina H             15q24-25               Hemopoietic               rs2289702                  G→A                      A*31:01                     0                        [6, 28]
ACC-6                        HMSD                   18q21.33               Hemopoietic               rs9945924                  G→A                        B*44                      17                          [6]
C19orf48                C19orf48                   19q13                        Broad                      rs3745526                  A→T                      A*02:01                  46,5                     [6, 19]
CD31                       PECAM1                    17q23                        Broad                          rs668                      C→G                        A*02                      52                         [27]
CD31                       PECAM1                    17q23                        Broad                        rs12953                  A→G/T                       A*02                      52                      [7, 29]
CTL7A7                    PANE-1                   22q13.2                Hemopoietic               rs5758511                  C→T                         A*03                      20                  [18, 28, 32]
DPH1                         DPH1                         17                           Broad                     rs35394823                 C→G                      B*5701                     4                          [28]
DRN-7                       SP110                     2q37.1                 Hemopoietic               rs1365776                  G→A                        A*03                      20                     [28, 32]
HA-1                       KIA A0223                 19p13.3                Hemopoietic               rs1801284                  A→G                        A*02,                     52,                        [32]
                                                                                                                                                                                                           A*02:06;                    0,
                                                                                                                                                                                                            B*40:01                     0                              
HA-2                         MYOG 1               7p13-p11.2             Hemopoietic              rs61739531                 G→A                      A*02:01                  46,5          [3, 7, 22, 28, 32, 26]
HA-3                            LBC                     15q24-25                     Broad                      rs7162168                  T→C                         A*01                      21             [3, 10, 27, 28, 32]
HA-8                       KIA A 0020                 9p24.2                       Broad                      rs2173904                  G→C                      A*02:01                  46,5      [3, 7, 10, 15, 28, 32, 25]
HB-1                           HB-1                      5q31.3                 Hemopoietic                rs161557                   C→T                     B*44:02,                    7,              [3, 13, 28, 32, 26]
                                                                                                                                                                                                            B*44:03                    20                             
HEATR-1                 HEATR-1                    1q43                         Broad                      rs2275687                  C→T                      B*08:01                    10                         [26]
LB-ADIR-1R             TOR3A                     1q25.2                 Hemopoietic               rs2296377                  T→C                      A*02:01                  46,5                       [28]
LB-ECGF-1H            ECGF                   22q13.33               Hemopoietic             rs112723255                C→T                        B*07                      11                         [28]
LB-LY75-1K                Ly75                       2q24.2                 Hemopoietic              rs12692566                 T→G                  DRB1*13:01                11                         [20]
LB-MTHFD1-1Q   MTHFD1                      14                     Hemopoietic               rs2236225                  G→A                  DRB1*03:01                14                         [20]
LB-PTK2B-1T           PTK2B                          8                      Hemopoietic                rs751019                   A→C                  DRB3*01:01               nd                        [20]
P2RX7                        P2RX7                         12                           Broad                      rs7958311              A→C/G/T                 DRB1*03                  16                         [26]
UTA2-1                    C12orf75                      12                           Broad                      rs2166807                  A→G                        A*02                      52                          [3]
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group of 46 donor/recipient pairs with the
aim to evaluate the accuracy and reliability
of the genotyping assay. A total of 2116
genotypes resulted out of a predicted total
number of 2116 (92 samples for 23 SNPs)
with a call rate of 100%.
In order to evaluate the accuracy and
reliability of the genotyping assay, two
different approaches were adopted.
Evaluation of method reproducibility was
carried out by genotyping of the DNA
number NA10859 during the Sequenom run.
This standard DNA is released the genotype
of only six (6 of 23, 26%; ACC-1, ACC-2,
ACC-6, HA-8, HB-1 and LB-ADIR-1R)
mHAgs. The concordance between the
released data and our genotyping was 100%.
In the second stage, we validated the set of
10 randomly selected samples using
conventional Sanger sequencing and also in
this case we obtained a concordance of
100%. The Hardy-Weinberg equilibrium
(HWE) was satisfied for most SNPs on both
populations (patients and donors).
rs12692566 (mHAgs LB-LY751K) was the
only SNP showing a significant difference as
compared with the prediction under HWE
assumptions. Since Hardy Weinberg
disequilibrium can indicate genotyping
errors or population stratification, LB-
LY751K was excluded from the statistical
analysis (Table 4).
mHAgs mismatches, patients’ clini-
cal features and correlation with
GvHD/GvL effects
The analysis of immunogenic
mismatches showed that sibling pairs had a
lesser number of mismatches compared to
MUD pairs (median 1 vs. 3; t-test with
P<0.003). The evaluation of genomic
mismatches point out that sibling pairs have
higher identity than MUD pairs (t-test,
P<0.0001). In fact, the median number of
genomic differences was 8 (range 0-15) in
sibling pairs and 13 (range 11-17) in MUD
pairs (t-test with P<0.05). Only one sibling
pair showed a perfect genomic mHAgs
match.
We also tried to correlate if some
mHAgs mismatches could be involved in
GvHD development. DPH1 genomic
mismatch resulted to be correlated with the
risk of grade ≥2 aGvHD development
(multivariate analysis HR 2.2, P=0.04, Table
5), while no mHAgs mismatches were found
to be correlated with an increased risk of
cGvHD (Table 5).
By these evidences, we investigated any
correlation between mHAgs mismatches and
RFS as a clinical surrogate of GvL effect.
Despite some clinical factors affecting the
RFS (i.e. the underlying disease, b3a2
transcript isoform and chronic GvHD
development), in multivariate analysis we
observed that only LB-ADIR-1R, with
genomic mismatch on graft versus host
direction (HR 0.3, P=0.03, Table 5) was
positively correlated with a better RFS.
Discussion
The study aimed to set up a new
laboratory assay for genotyping minor
histocompatibility antigens which are
thought to play a key role in the allo-immune
responses in fully HLA-matched stem cell
transplantations.
The MALDI-TOF iPLEX gold approach
was used to overcome the limits of
conventional methods, such as SSP-PCR and
Luminex, and to make mHAgs genotyping
analysis suitable for clinical application.
PCR-SSP and Luminex are commonly used
for HLA typing, but both methods have
several limitations. Complex primer design
and identification of the annealing
temperature are critical for the PCR-SSP
test; while biotinylated DNA probes, beads
and streptavidin-phycoerythrin binding are
critical steps for Luminex.34,35 MALDI-TOF
was used effectively for KIR (killer-cell
immunoglobulin-like receptor) and platelet
antigens genotyping and, due to the expected
advantages in terms of rapidity, simplicity
and high throughput capability, it was
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Table 3. Primers using for MALDI-TOF assays are listed; PCR primers tags are in bold, no-template bases are reported in lower case
letters.
Multiplex    mHAg            SNP             Amplification Primer                                                                           Extension Primer
                                                              Forward                               Reverse                                             
1                          ACC-1                   rs1138357         ACGTTGGATGTTGGACCTGATCCAGGTTGT         ACGTTGGATGTATTTACAGGCTGGCTCAGG                         GTGGTATCTGTAGGACG
                            ACC-2                   rs3826007         ACGTTGGATGTGGTTACAATTCTTCCCCAG          ACGTTGGATGCTGCCAGAACACTATTCAAC                           tcCAATTCTTCCCCAGTTAATGATG
                            ACC-6                   rs9945924         ACGTTGGATGGAAGTCCAGCTCAACTGATA          ACGTTGGATGCACTGCAGCTCAGATGTCTC                         TTGTCTTGAAGTGGCTTTA
                            C19orf48              rs3745526         ACGTTGGATGCACGCCTAGGCAGGAAACA           ACGTTGGATGTTTTCTGTGTCCTTCCCCTG                          GCCTAGGCAGGAAACAGCAGAG
                            DRN7                    rs1365776         ACGTTGGATGCTTCCTCTTGTACTCTCATC           ACGTTGGATGAGATGTATCTGGTCAACTCC                          aaTCTTGTACTCTCATCTTACCTC
                            HA-1                      rs1801284         ACGTTGGATGGCCTTGAGAAACTTAAGGAG         ACGTTGGATGTTGGGTCTGGCTCTGTCTTC                         AGGAGTGTGTGTTGC
                            HA-2                      rs61739531       ACGTTGGATGATGGCCTCAGGCCCATACAG         ACGTTGGATGCGCATCTACACCTACATCGG                          aTCCTGGTAGGGGTTCA
                            HA-8                      rs2173904         ACGTTGGATGGTTTTGTTGCAGTCAGCAG           ACGTTGGATGGTTCTAATTTTTCTGGCTG                             TGTTGCAGTCAGCAGATCACC
                            LB-ADIR-1R        rs2296377         ACGTTGGATGGTCCGTGGCGCCAGCTTTG          ACGTTGGATGTGGAGGCGCCGCGGGGCTCA                      CCAGCTTTGGCTCTTT
                            LB-ECGF1           rs112723255     ACGTTGGATGAGGAGGCGCTCGTACTCTC          ACGTTGGATGAAGGAGCTTTATTGCTGCGG                         gCGTACTCTCCGACCGC
                            LB-LY751K           rs12692566       ACGTTGGATGTGGGGTCTTATCAAACCAC            ACGTTGGATGGTCTTGATTTAATCTCTAAGC                         GGTCTTATCAAACCACATAAGAGA
                            LB-MTHFD1        rs2236225         ACGTTGGATGTAACCTACAAACCCTTCTGG          ACGTTGGATGACATCGCACATGGCAATTCC                          ccCTGGGCCAACAAGCTTGAGTGCGATC
                            P2RX7                   rs7958311         ACGTTGGATGTGGTGGTCTTGTCGTCAAGG        ACGTTGGATGAGATCTACTGGGACTGCAAC                          gCAAGGCGACGGAAACTGTATTTGGGA
                            UTA2-1                 rs2166807         ACGTTGGATGAGCTGAGGTCTGCCTTGATG        ACGTTGGATGACCACATACATCATTGCAAG                           CTTGATGGTAAAGTTAATACAGAATTT
2                          ACC-4/5                rs2289702         ACGTTGGATGACCGCAGACGGGGACTCCCA       ACGTTGGATGATGTGGGCCACGCTGCCGCT                        TCCCAGGAGCCAGGCCC
                            CD31                     rs668                 ACGTTGGATGGCTCAGTTCCAAGGACTCAC         ACGTTGGATGGTACTGTGATTGTGAACAAC                          CACCTTCCACCAACA
                            CTL7A7                 rs5758511         ACGTTGGATGTTGAGCACACCAGGCAAGTC        ACGTTGGATGACGGAGATACCTCGTGGAAG                         CACACCAGGCAAGTCCCACACTC
                            DPH1                    rs35394823       ACGTTGGATGTGCTGCTCTCTGAGATCTTC         ACGTTGGATGATAGCCAGGCAGATACTCAC                          CCCAGCAAGCTTAGC
                            HA-3                      rs7162168         ACGTTGGATGATGATGATGGGGCCCCAGC          ACGTTGGATGTAGAGAGGGAGTGCTCCTTT                         cCTGGTGTGAGGGAAGTCA
                            HB-1                     rs161557           ACGTTGGATGCTCAAGTCTCAGCTAAGCCA          ACGTTGGATGCTTCAACTTCAACCAATTCC                           CCATTCTTTTCTATAGGTTCTCTG
                            HEATR1                rs2275687         ACGTTGGATGCTTCCTTTTTGATACCCAGC          ACGTTGGATGTGGTTACCTGATCCACCAGA                          TTTATAAGTAAAGAGAGAGCAG
                            LB-PDK2B           rs751019           ACGTTGGATGTGTTTCTTCCTCTGCAGGAC         ACGTTGGATGTCTCCTGGCAACTCACCAAT                          CCCCATGGTTTATATGAATGATA
3                          CD31                     rs12953             ACGTTGGATGGGCTGTGCAGTAATACTCTC         ACGTTGGATGAATGCCACCCAGGCATTTTG                          CCCTCCTGTTCCTTG
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identified as a potential new method for
mHAgs genotyping.36,37 From a technical
point of view, one of the main advantages of
SNPs genotyping by MS system consists in
the direct measurement of the mass of the
molecules of interest without using any
surrogate, such as fluorescence. MS
genotyping has shown high accuracy;
moreover, this methodology is rapid and
highly automated, with a genotyping
throughput of up to 128 matched pairs (256
samples) per run. The MS approach presents
other advantages: it requires only a small
amount of DNA, it is highly reproducible,
and, furthermore, it works on multiplex and
the design of each multiplex is made directly
by the instrument software. The only
drawbacks of this method are that it does not
allow the genotyping of mHAgs resulting
from deletions and can be used only if both
the polymorphism and the polymorphism’s
flanking region are known.36 The use of
designed primers for SNPs of interest and
the MS protocol in this training set allowed
us to genotype 100% of the SNPs (2116
genotypes of a predicted total number of
2116) and mHAgs. Intra- and extra-run
controls demonstrated the reliability of this
method. Analyzing the data obtained by
genotyping the mHAgs of this set of
donor/recipient pairs with their clinical
features, particularly GvHD development
and RFS, some interesting suggestions have
emerged.
Sibling pairs have fewer mHAgs
disparities despite the pairs with HLA-
matched unrelated donor (P<0.0001). This
data may appear obvious, but from a
biological point of view no study has clearly
shown that until now. This means that the
genomic compatibility of HLA full matched
MUD pairs will never be greater than full
HLA sibling pairs.
Established that HLA differences
between donor and recipient are the major
predictor of GvHD, we investigated a
possible role of mHAgs on GvHD
development and relapse incidence in a
training set of Ph-positive CML and ALL
allotransplanted patients. These patients
were chosen because representative of
chronic and acute leukemias sharing a
unique cytogenetic alteration: t(9;22). The
only observation is that genomic DPH1
mismatch appeared to be related to an
increased risk of grade ≥2 aGvHD
development. This possible correlation
between DPH1 and aGvHD is supported by
the fact that DPH1 is expressed by a broad
range of non-hematopoietic tissues. The role
of DPH1 on extramedullary toxicity has
already been described by Warren, who
pointed out that pulmonary toxicity was
observed with infusion of DPH1-specific T Ta
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cells. On the contrary, leukemic blasts were
poorly recognized by DPH1-specific T
cells.43
Conversely, we found that genomic
mismatch of LB-ADIR-1R on graft versus
host direction was related to a better RFS.
Our findings on LB-ADIR-1R mismatch are
consistent with previous data from van
Bergen, showing that LB-ADIR-1R specific
T cells perform wide-reaching antitumor
activity with a limited recognition of non-
activated tissues. Indeed, LB-ADIR-1R
specific T cell recognize cell lines from
haematological tumours, while generally
mesenchymal and biliary epithelial cells are
recognized to be GvHD target tissues.14
Conclusions
This work prove that MS may be a
simple, effective, and accurate method for
mHAgs genotyping. The method requires a
small amount of gDNA that can be easily
extracted also from cryopreserved cells.
Furthermore, MS is able to genotype all
mHAgs in a single work session, thus saving
a lot of time.
Data analysis of our patients training set
lead us to say that despite the full major
HLA match, the minor-HLA genomic and
immunogenic compatibility between a
patient and his unrelated donor is always
lower compared to the genomic and
immunogenic compatibility of a patient and
his sibling donor. In fact, sibling pairs had a
lesser number of mHAgs mismatches
compared to MUD pairs (P=0.003). Of 23
mHAgs evaluated, only 2, DPH1 and LB-
ADIR-1R, proved to be correlated with the
GvHD and GvL effect respectively, and
these results confirm the previous reports.
Our study suggests that MS would be used
and useful for mHAgs genotyping. A larger
and prospective trial would be warranted to
validate this method. 
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Table 5. Multivariate analysis of relationship btween mHAgs and aGvHD, cGvHD or RFS.
                  Grade ≥2 aGvHD, HR (p)                                   cGvHD, HR (p)                                                             RFS, HR (p)
ACC-1                                      ns                                                                                     ns                                                                                                        ns
ACC-2                                      ns                                                                                     ns                                                                                                        ns
ACC-4                                      ns                                                                                     ns                                                                                                        ns
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